Promise Clarifies NAD+ Classification Amid Federal Peptide Policy Review

SCOTTSDALE, AZ / ACCESS Newswire / November 4, 2026 /Promise, operated by myPromise, LLC, today announced a clarification of how NAD+ is classified and prescribed, as federal officials review a proposed policy on compounding certain peptides.

The announcement distinguishes NAD+, a coenzyme involved in cellular metabolism, from peptides and explains why the federal review does not itself change the regulatory status of compounded NAD+ injections. Promise is outlining the distinction to help patients understand the scientific and regulatory context surrounding prescription treatment options.

The White House Office of Information and Regulatory Affairs lists the HHS-FDA notice, "Interim Access Policy for Compounding Using Certain Peptides, " as received on October 14, 2026, and pending review. Reuters reported on the filing the following day, noting that its substantive terms had not been disclosed. Promise 's clarification addresses the scientific and prescribing distinctions relevant to NAD+ without suggesting that the proposed policy determines its regulatory position.

NAD+ Classification and Compounding Status

The National Library of Medicine 's PubChem database identifies nicotinamide adenine dinucleotide (NAD) as a coenzyme that operates in oxidized NAD+ and reduced NADH forms. NAD+ participates in redox reactions involved in cellular energy metabolism and also supports enzyme activity, as described in a review in Nature Reviews Molecular Cell Biology. These biochemical functions explain NAD+ 's role in cells, but they do not establish that injections produce particular clinical outcomes.

The regulatory distinction is equally important. The FDA states in its compounding guidance that compounded drugs are not FDA-approved and are not reviewed by the agency before marketing for safety, effectiveness or quality. The FDA 's July 2026 Pharmacy Compounding Advisory Committee agenda listed seven peptide-related substances for discussion; NAD+ was not among them. Advisory discussions and pending policy reviews should not be interpreted as approval decisions or as evidence of a policy change for NAD+.

Promise 's Prescriber-Led Process

Promise describes its NAD+ service as a clinician-guided telehealth process rather than direct medication sales. Adults complete a treatment-specific health questionnaire for review by an independent licensed provider, who determines whether prescribing is appropriate and may decline a request. If a prescription is issued, Promise reports that a licensed U.S. compounding pharmacy prepares the prescribed injectable, with temperature-safe delivery and care-team follow-up. Availability may vary by state.

Patients considering prescription NAD+ at Promise can review the service details before completing the online medical evaluation. The decision to prescribe remains with the individual licensed provider, and the service description does not establish clinical efficacy or guarantee that treatment will be offered. Evidence concerning NAD+ biology or studies of NAD+ precursors should not be treated as proof of benefits from compounded NAD+ injections.

Methodology

This release is based on the October 22, 2026, OIRA status snapshot, Reuters ' October 15 reporting, FDA compounding guidance and its July 2026 advisory agenda, PubChem 's NAD reference, peer-reviewed scientific reviews, and Promise 's published service description, without original clinical research or independent testing.

FAQs

Does the federal peptide-policy review change NAD+ injection status?

Promise 's clarification distinguishes NAD+ from the peptides covered by the pending review. The filing itself is not a final policy decision, and its status does not establish a regulatory change for compounded NAD+ injections.

What does NAD+ 's role in cellular energy metabolism prove?

Promise 's service information describes NAD+ as a coenzyme involved in cellular processes. This biochemical role does not, on its own, demonstrate that injectable NAD+ improves energy, cognition, recovery, longevity or other clinical outcomes.

What does "not FDA-approved " mean for compounded NAD+?

Promise offers NAD+ as a prescribed compounded injectable, but compounded medications are not FDA-approved. The FDA does not review them before marketing for safety, effectiveness and quality in the same manner as approved drugs, making it important to distinguish a prescription from FDA approval.

About Promise

Promise, operated by myPromise, LLC, is a Scottsdale, Arizona-based telehealth service connecting adults with independent licensed providers for assessment of prescription treatments.

Media Contact

Contact:Stacey Grant
Email:stacey@mypromise.com
Location:Scottsdale, Arizona, USA

SOURCE: Promise

View the original press release on ACCESS Newswire

© 2026 ACCESS Newswire. All Rights Reserved.